New Drug July 16, 2026 8 min read

Orforglipron: Eli Lilly's Oral GLP-1 Pipeline Update

Key Takeaways

Orforglipron (brand name Foundayo) received FDA approval April 1, 2026 — it is no longer a pipeline drug
It's the first oral non-peptide GLP-1, meaning no fasting requirement and no SNAC absorption enhancer needed
Entry pricing starts at ~$149/month, with maintenance doses at $299–349/month
Available through LillyDirect and expanding telehealth/pharmacy channels
Eli Lilly is also developing oral tirzepatide, which is still in clinical trials

Orforglipron is no longer a pipeline product — Eli Lilly's oral small-molecule GLP-1 received FDA approval on April 1, 2026 under the brand name Foundayo. Here's what that means for the oral GLP-1 market, how it compares to oral Wegovy, and what's still in Lilly's pipeline.

What Makes Orforglipron Different

Every other oral GLP-1 on the market is a peptide — a fragile chain of amino acids that stomach acid wants to destroy. That's why oral Wegovy and Rybelsus require the SNAC absorption enhancer and the 30-minute fasting protocol. Orforglipron is a small molecule, not a peptide. It's chemically stable in the GI tract without any absorption tricks.

The practical difference for patients is significant:

No fasting required — take it with or without food, any time of day
No water restriction — drink normally
Room-temperature storage — no refrigeration needed
Daily tablet — same convenience as a vitamin

Clinical Data

The ATTAIN trials (orforglipron's Phase 3 program) showed meaningful weight loss results:

Trial	Population	Weight Loss (highest dose)	Duration
ATTAIN-1	Obesity/overweight without diabetes	~14.7% body weight	72 weeks
ATTAIN-2	Type 2 diabetes + obesity	~9.4% body weight	40 weeks

These results are competitive with oral Wegovy 25 mg (15–17% in OASIS trials) though direct head-to-head data is limited. The GI side-effect profile is similar to other GLP-1s: nausea, diarrhea, and vomiting are the most common adverse events, generally peaking during titration.

Manufacturer: Eli Lilly

Doses: Multiple dose strengths (titration schedule)

Pricing: Entry ~$149/mo · Maintenance ~$299–349/mo

Notes: FDA-approved April 1, 2026. First oral non-peptide GLP-1. No fasting requirement — can be taken with food.

Learn more at LillyDirect (manufacturer program — not an affiliate link)

Pricing and Access

Eli Lilly has priced Foundayo competitively against oral Wegovy. Entry pricing at the starting dose is approximately $149/month, with maintenance doses in the $299–349/month range. LillyDirect (Lilly's direct-to-patient platform) is the primary distribution channel, similar to how Zepbound is sold directly.

The Medicare GLP-1 Bridge program covers Foundayo at the same $50/month flat copay as Wegovy and Zepbound, effective July 1, 2026.

What's Still in Lilly's Pipeline

Foundayo is just the first oral product from Lilly. The company is also developing:

Oral tirzepatide: A pill version of Zepbound/Mounjaro. Still in clinical trials — no FDA approval timeline announced
Retatrutide: A triple-agonist (GLP-1/GIP/glucagon) being tested in injectable form. Oral formulation is earlier-stage

Compounded Alternatives

While Foundayo is new, compounded oral GLP-1 options have been available from telehealth providers for longer. These offer a lower price point, though they use different formulations (typically compounded semaglutide or tirzepatide in oral or sublingual form).

MadeMed

Oral Semaglutide

Compounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.

From $89/mo (quarterly) Oral semaglutide

⚕️ This is a compounded medication — prepared by a licensed pharmacy to a provider's prescription. Compounded drugs are not FDA-approved and do not undergo FDA review for safety, efficacy, or manufacturing standards.

Visit MadeMed → Paid link · We may earn a commission

Telos Rx

Oral Tirzepatide

Compounded oral tirzepatide via Telos Rx. First-month pricing starts at $40; ongoing pricing varies by plan length ($160–249/mo).

From $40/first month Oral tirzepatide

Visit Telos Rx → Paid link · We may earn a commission

Bottom Line

Foundayo's approval is the biggest shift in the oral GLP-1 market since Wegovy's pill launched in December 2025. The no-fasting convenience, competitive pricing, and Medicare Bridge coverage make it a legitimate alternative to oral Wegovy. The remaining question is how quickly insurance formularies and telehealth platforms incorporate it — that process is underway but still early.

Information current as of July 2026. Foundayo is a prescription medication. Consult your healthcare provider about eligibility.

OralGLP-1s Editorial Team

Independent oral GLP-1 medication research. We track every pill, troche, and sublingual format available in the U.S. — FDA-approved and compounded. Not medical advice.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Individual results, eligibility, and pricing may vary. Always consult your physician before starting, stopping, or changing any medication. Compounded medications are not FDA-approved.